,50,51 Studies to gain a better understanding of the regulation of SMN expression are vital, as they will have important implications for the optimization of current gene-targeting therapies, and to identify novel therapeutic targets for the development of second-generation therapies for SMA. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.